US 9,809,651 B2
Method of treating cancer with an EGFR targeted immunomodulatory fusion protein
Nagaraj Govindappa, Karnataka (IN); Kedarnath Sastry, Karnataka (IN); and Maria Melina Soares, Karnatake (IN)
Assigned to BIOCON LIMITED, (IN)
Filed by BIOCON LIMITED, Bangalore (IN)
Filed on Feb. 18, 2016, as Appl. No. 15/47,062.
Application 14/458,674 is a division of application No. 13/779,409, filed on Mar. 13, 2013, granted, now 8,815,247.
Application 15/047,062 is a continuation of application No. 14/458,674, filed on Aug. 13, 2014.
Claims priority of application No. 1689/CHE/2012 (IN), filed on Apr. 30, 2012; and application No. 1690/CHE/2012 (IN), filed on Apr. 30, 2012.
Prior Publication US 2016/0168260 A1, Jun. 16, 2016
Int. Cl. C07K 16/28 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); C07K 14/495 (2006.01); C07K 14/71 (2006.01); C07K 14/00 (2006.01); C07K 14/65 (2006.01); C07K 14/705 (2006.01); C07K 16/32 (2006.01); G01N 33/68 (2006.01); A61K 45/06 (2006.01); C07K 7/08 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 38/10 (2013.01); A61K 38/179 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); C07K 14/495 (2013.01); C07K 14/65 (2013.01); C07K 14/70532 (2013.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); G01N 33/6854 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/732 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/33 (2013.01)] 6 Claims
 
1. A method of treating cancer by reducing proliferation of cancer cells, the method comprising contacting cancer cells with a therapeutic amount of chimeric fusion protein, wherein the chimeric fusion protein comprises a targeting moiety to target a cancer cell and an immunomodulating moiety that counteracts immune tolerance, wherein the targeting moiety and the immunomodulating moiety are linked by an amino acid spacer of sufficient length of amino acid residues so that both moieties can successfully bind to their individual targets, wherein the immunomodulating moiety is TGFβRII comprising SEQ ID NO: 4, wherein the amino acid spacer is selected from SEQ ID NO: 3 or SEQ ID NO: 11; and wherein the targeting moiety consists of a light chain of an Anti-EGFR1 antibody; wherein SEQ ID NO: 4 is attached via the amino acid spacer to the C-terminus of the light chain SEQ ID NO: 6 of the Anti-EGFR1 antibody.